Resources from the same session
LBA81 - Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab + CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Florian Lordick
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
LBA82 - Updated efficacy and safety results from phase III SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma
Presenter: Jaffer Ajani
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA81 and LBA82
Presenter: Sylvie Lorenzen
Session: Mini oral session 1 - Gastrointestinal tumours, upper digestive
Resources:
Slides
Webcast